How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...
Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...
Chris Gibson built the pioneering AI biotech Recursion Pharmaceuticals on a foundation of bold promises. But after more than a decade at the helm, Gibson stepped down as CEO in November 2025. And his ...
Recursive Superintelligence, founded by former Google, Meta and OpenAI researchers, is part of a growing effort to automate the creation of artificial intelligence. By Cade Metz Reporting from San ...
Blue Owl Capital-owned data center firm Stack Infrastructure is reportedly considering the sale of its Asia operations, in a transaction valued at more than $30 billion. Reporting from Bloomberg, ...
May 6 (Reuters) - Stack Infrastructure, a data centre firm owned by Blue Owl Capital, is considering its options, including a sale of its Asia operations in a deal valued at more than $30 billion, ...
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
Theater in the round—also called an arena stage, central stage, or island stage—is a type of stage that’s surrounded by audience members on all sides. Typically, the stage is on the ground level, or ...
Adam Hayes, Ph.D., CFA, is a financial writer with 15+ years Wall Street experience as a derivatives trader. Besides his extensive derivative trading expertise, Adam is an expert in economics and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results